Marginal Zone Lymphoma – Epidemiology – Epidemiology – Marginal Zone Lymphoma – Mature Markets
Clarivate Epidemiology’s coverage of marginal zone lymphoma (MZL) comprises epidemiological estimates of key patient populations in the major mature pharmaceutical markets (the United States, France, Germany, Italy, Spain, the United Kingdom, and Japan). We report both the diagnosed incidence and diagnosed prevalence of MZL for each country, as well as annualized case counts projected to the national population.
Most patient populations are forecast over a period of 20 years for the major mature pharmaceutical markets. In addition to forecasting incident and prevalent patient populations, we estimate the number of drug-treatment opportunities in specific lines of therapy in the major mature pharmaceutical markets.
Clarivate Epidemiology’s MZL forecast will answer the following questions:
- How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of MZL over the forecast period?
- Of all people diagnosed with MZL, how many in each of the major mature pharmaceutical markets are drug-treated?
All forecast data are available on the Clarivate Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is provided for full transparency into research and methods.
In addition to the total number of incident cases for each forecast year, Clarivate Epidemiology provides at least 10 years of forecast data for the following MZL subpopulations:
- Diagnosed incident cases of extranodal MALT MZL with baculoviral IAP repeat-containing 3-mucosa-associated lymphoid tissue lymphoma translocation gene 1 (BIRC3-MALT1) fusion.
- Diagnosed prevalent cases of MZL.
- Diagnosed drug-treatable cases.
- Diagnosed drug-treated cases.
Note: Coverage may vary by country.
Table of contents
- Marginal Zone Lymphoma - Epidemiology - Epidemiology - Marginal Zone Lymphoma - Mature Markets
- Epidemiology Data
- Methods
- Literature review (studies included in/excluded from the analyses of marginal zone lymphoma)
- Diagnosed incident cases of marginal zone lymphoma
- Diagnosed incident cases of BIRC3-MALT1 fusion extranodal MALT marginal zone lymphoma
- Diagnosed prevalent cases of marginal zone lymphoma
- Drug-treatable populations
- Drug-treated populations
- Risk/protective factors applied to disease forecast models
- Reference Materials
